To study the mechanisms of John Cunningham virus (JCV) infection causing progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

Trial Profile

To study the mechanisms of John Cunningham virus (JCV) infection causing progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top